Pizzo S V, Lewis J G, Campbell E E, Dreyer N A
Contraception. 1981 Feb;23(2):181-6. doi: 10.1016/0010-7824(81)90103-7.
A case-control study of fibrinolytic activity was conducted comparing 12 women with a recent history of thromboembolism while taking oral contraceptives and 28 matched female controls without a history of thromboembolism. All subjects had stopped using oral contraceptives at least 12 months prior to study. A new assay, recently developed in this laboratory, was used to evaluate the mean fibrinolytic response to venous occlusion in both cases and controls. The fibrinolytic response of all subjects was stratified into quartiles as previously described. While the controls segregated as expected, all 12 cases occurred in subjects whose fibrinolytic response fell in the first two quartiles with 8 of the 12 subjects having first quartile responses. The mean fibrinolytic response for all controls was 12.3 units while cases showed a mean response of only 3.9 units. The above data supports and extends our recent suggestion that low fibrinolytic response may signal a natural predisposition to venous thromboembolism which could be triggered by use of synthetic estrogens. However, these data do not support the use of this assay as a screening test for oral contraceptive related risk to thromboembolism since at least 50% of the control population also segregate in the first two quarters.
开展了一项关于纤溶活性的病例对照研究，比较了12名近期有血栓栓塞病史且正在服用口服避孕药的女性与28名匹配的无血栓栓塞病史的女性对照。所有受试者在研究前至少12个月停止使用口服避孕药。本实验室最近开发的一种新检测方法用于评估病例组和对照组对静脉闭塞的平均纤溶反应。如前所述，所有受试者的纤溶反应被分为四分位数。虽然对照组的分布符合预期，但所有12例病例均发生在纤溶反应处于前两个四分位数的受试者中，12名受试者中有8名的纤溶反应处于第一个四分位数。所有对照组的平均纤溶反应为12.3单位，而病例组的平均反应仅为3.9单位。上述数据支持并扩展了我们最近的观点，即纤溶反应低可能表明存在静脉血栓栓塞的自然易感性，这种易感性可能由合成雌激素的使用引发。然而，这些数据不支持将该检测方法用作口服避孕药相关血栓栓塞风险的筛查试验，因为至少50%的对照人群也分布在前两个四分位数中。
